CO2019013669A2 - Anticuerpos anti-garp-tgf-β - Google Patents
Anticuerpos anti-garp-tgf-βInfo
- Publication number
- CO2019013669A2 CO2019013669A2 CONC2019/0013669A CO2019013669A CO2019013669A2 CO 2019013669 A2 CO2019013669 A2 CO 2019013669A2 CO 2019013669 A CO2019013669 A CO 2019013669A CO 2019013669 A2 CO2019013669 A2 CO 2019013669A2
- Authority
- CO
- Colombia
- Prior art keywords
- garp
- tgf
- antibodies
- complex
- human
- Prior art date
Links
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 abstract 1
- 101000771075 Homo sapiens Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 abstract 1
- 101001004924 Homo sapiens Transforming growth factor beta activator LRRC32 Proteins 0.000 abstract 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 abstract 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 abstract 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 abstract 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 abstract 1
- 102000052917 human LRRC32 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpos, y fragmentos de unión al antígeno de los mismos, que se unen a un complejo de GARP y TGF-β1, en particular un complejo de la GARP humana y el TGF-β1 humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1707561.5A GB201707561D0 (en) | 2017-05-11 | 2017-05-11 | GARP-TGF-beta antibodies |
| PCT/EP2018/062251 WO2018206790A1 (en) | 2017-05-11 | 2018-05-11 | GARP-TGF-β ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019013669A2 true CO2019013669A2 (es) | 2020-04-01 |
Family
ID=59201573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0013669A CO2019013669A2 (es) | 2017-05-11 | 2019-12-04 | Anticuerpos anti-garp-tgf-β |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US10479829B2 (es) |
| EP (3) | EP4086286A1 (es) |
| JP (2) | JP7118135B2 (es) |
| KR (2) | KR20240065192A (es) |
| CN (1) | CN110945027B (es) |
| AU (2) | AU2018265241B2 (es) |
| BR (1) | BR112019023735A8 (es) |
| CA (1) | CA3061841C (es) |
| CL (1) | CL2019003211A1 (es) |
| CO (1) | CO2019013669A2 (es) |
| CR (1) | CR20190561A (es) |
| CY (1) | CY1125674T1 (es) |
| DK (1) | DK3606961T3 (es) |
| DO (1) | DOP2019000285A (es) |
| EC (1) | ECSP19087742A (es) |
| ES (1) | ES2921015T3 (es) |
| GB (1) | GB201707561D0 (es) |
| HR (1) | HRP20220787T1 (es) |
| HU (1) | HUE059237T2 (es) |
| IL (2) | IL270236B2 (es) |
| LT (1) | LT3606961T (es) |
| MX (1) | MX385670B (es) |
| MY (1) | MY199335A (es) |
| NZ (1) | NZ758647A (es) |
| PE (1) | PE20200618A1 (es) |
| PH (1) | PH12019502526A1 (es) |
| PL (1) | PL3606961T3 (es) |
| PT (1) | PT3606961T (es) |
| RS (1) | RS63361B1 (es) |
| RU (1) | RU2767784C2 (es) |
| SG (1) | SG10201914130VA (es) |
| SI (1) | SI3606961T1 (es) |
| SM (1) | SMT202200284T1 (es) |
| UA (1) | UA125534C2 (es) |
| WO (1) | WO2018206790A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057881A1 (fr) * | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Procede de stabilisation d'une proteine |
| EP3436480A4 (en) * | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION |
| EP4021498A4 (en) | 2019-08-28 | 2024-01-03 | Chugai Seiyaku Kabushiki Kaisha | CROSS-SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE |
| US20240190961A1 (en) | 2019-10-25 | 2024-06-13 | Daiichi Sankyo Company, Limited | Combination of anti-garp antibody and immunomodulator |
| CN115190812A (zh) * | 2020-01-11 | 2022-10-14 | 供石公司 | TGFβ抑制剂及其用途 |
| KR20220143063A (ko) | 2020-02-19 | 2022-10-24 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 TGFβ 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| WO2021231732A1 (en) * | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| CN116723861A (zh) * | 2020-12-02 | 2023-09-08 | 上海复宏汉霖生物技术股份有限公司 | 抗GARP/TGFβ抗体及使用方法 |
| EP4279509A4 (en) * | 2021-01-18 | 2024-12-25 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | GARP PROTEIN ANTIBODY AND ITS APPLICATION |
| TW202413392A (zh) | 2022-05-18 | 2024-04-01 | 美商韋斯塔隆公司 | 殺蟲ａｃｔｘ肽變異體 |
| WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
| WO2024023797A1 (en) | 2022-07-29 | 2024-02-01 | Abbvie Biotherapeutics Inc. | ANTI-GARP-TGF-β1/PD-1 COMBINATION THERAPY |
| CN120418286A (zh) | 2023-01-09 | 2025-08-01 | 北京拓界生物医药科技有限公司 | TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途 |
| WO2024164807A1 (zh) * | 2023-02-06 | 2024-08-15 | 贝达药业股份有限公司 | 多特异性抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| NZ298145A (en) | 1994-12-29 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| ES2304069B1 (es) * | 2003-08-22 | 2009-08-12 | Proyecto De Biomedicina Cima, S.L. | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| WO2006103639A2 (en) | 2005-03-31 | 2006-10-05 | Case Western Reserve University | Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals |
| US20110086367A1 (en) | 2006-04-03 | 2011-04-14 | Medizinische Hochschule Hannover | Pharmaceuticals for influencing the reaction of the human immune system |
| WO2009073163A1 (en) | 2007-12-03 | 2009-06-11 | American Type Culture Collection (Atcc) | Avian influenza antibodies, compositions, and methods thereof |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US8951793B2 (en) | 2008-08-21 | 2015-02-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of making an isolated population of FOXP3+ regulatory T cells |
| KR101492052B1 (ko) | 2012-06-26 | 2015-02-10 | (주)대창솔루션 | 액화가스 운반용 탱크 |
| JP6391574B2 (ja) | 2012-08-31 | 2018-09-26 | アルゲン−エックス ビーブイビーエー | 種間標的内交差反応性を有する抗体分子を産生する方法 |
| DK2981822T3 (da) | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Sammensætninger og fremgangsmåder til vækstfaktormodulation |
| CN113583128A (zh) | 2013-08-01 | 2021-11-02 | 鲁汶大学 | 抗garp蛋白及其用途 |
| EP2832747A1 (en) * | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
| EP3253796A1 (en) | 2015-02-03 | 2017-12-13 | Université Catholique de Louvain | Anti-garp protein and uses thereof |
| FI3354729T3 (fi) * | 2015-09-24 | 2024-04-23 | Daiichi Sankyo Co Ltd | Anti-garp-vasta-aine |
| BR112019000621A2 (pt) * | 2016-07-14 | 2019-04-24 | Scholar Rock, Inc. | anticorpos tgfss, métodos e usos |
-
2017
- 2017-05-11 GB GBGB1707561.5A patent/GB201707561D0/en not_active Ceased
-
2018
- 2018-05-11 IL IL270236A patent/IL270236B2/en unknown
- 2018-05-11 EP EP22168997.9A patent/EP4086286A1/en not_active Withdrawn
- 2018-05-11 BR BR112019023735A patent/BR112019023735A8/pt unknown
- 2018-05-11 EP EP23189977.4A patent/EP4282430A3/en active Pending
- 2018-05-11 CN CN201880046262.8A patent/CN110945027B/zh active Active
- 2018-05-11 RU RU2019140602A patent/RU2767784C2/ru active
- 2018-05-11 NZ NZ758647A patent/NZ758647A/en unknown
- 2018-05-11 KR KR1020247014708A patent/KR20240065192A/ko active Pending
- 2018-05-11 HR HRP20220787TT patent/HRP20220787T1/hr unknown
- 2018-05-11 RS RS20220600A patent/RS63361B1/sr unknown
- 2018-05-11 WO PCT/EP2018/062251 patent/WO2018206790A1/en not_active Application Discontinuation
- 2018-05-11 LT LTEPPCT/EP2018/062251T patent/LT3606961T/lt unknown
- 2018-05-11 EP EP18728524.2A patent/EP3606961B8/en active Active
- 2018-05-11 HU HUE18728524A patent/HUE059237T2/hu unknown
- 2018-05-11 KR KR1020197036577A patent/KR102664663B1/ko active Active
- 2018-05-11 PL PL18728524.2T patent/PL3606961T3/pl unknown
- 2018-05-11 MY MYPI2019006528A patent/MY199335A/en unknown
- 2018-05-11 IL IL305613A patent/IL305613A/en unknown
- 2018-05-11 ES ES18728524T patent/ES2921015T3/es active Active
- 2018-05-11 CR CR20190561A patent/CR20190561A/es unknown
- 2018-05-11 PE PE2019002382A patent/PE20200618A1/es unknown
- 2018-05-11 US US15/977,449 patent/US10479829B2/en active Active
- 2018-05-11 AU AU2018265241A patent/AU2018265241B2/en active Active
- 2018-05-11 MX MX2019013490A patent/MX385670B/es unknown
- 2018-05-11 CA CA3061841A patent/CA3061841C/en active Active
- 2018-05-11 PT PT187285242T patent/PT3606961T/pt unknown
- 2018-05-11 SG SG10201914130VA patent/SG10201914130VA/en unknown
- 2018-05-11 SI SI201830702T patent/SI3606961T1/sl unknown
- 2018-05-11 SM SM20220284T patent/SMT202200284T1/it unknown
- 2018-05-11 JP JP2020512919A patent/JP7118135B2/ja active Active
- 2018-05-11 UA UAA201911783A patent/UA125534C2/uk unknown
- 2018-05-11 DK DK18728524.2T patent/DK3606961T3/da active
-
2019
- 2019-05-10 US US16/409,679 patent/US10875914B2/en active Active
- 2019-11-08 DO DO2019000285A patent/DOP2019000285A/es unknown
- 2019-11-08 CL CL2019003211A patent/CL2019003211A1/es unknown
- 2019-11-11 PH PH12019502526A patent/PH12019502526A1/en unknown
- 2019-11-27 US US16/698,833 patent/US10793627B2/en active Active
- 2019-12-04 CO CONC2019/0013669A patent/CO2019013669A2/es unknown
- 2019-12-10 EC ECSENADI201987742A patent/ECSP19087742A/es unknown
-
2020
- 2020-11-12 US US17/096,931 patent/US20210324061A1/en not_active Abandoned
-
2021
- 2021-09-30 AU AU2021240255A patent/AU2021240255A1/en not_active Abandoned
-
2022
- 2022-06-29 CY CY20221100444T patent/CY1125674T1/el unknown
- 2022-08-01 JP JP2022122483A patent/JP2022169549A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019013669A2 (es) | Anticuerpos anti-garp-tgf-β | |
| ECSP19078429A (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| AR132864A2 (es) | UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO | |
| ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
| MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| CO2019013935A2 (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| UY37030A (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
| PE20170288A1 (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno | |
| MX2024006565A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| MX373245B (es) | Anticuerpos cd3 humanizados o quiméricos. | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| MX2015012872A (es) | Anticuerpos anti-tau y metodos de uso. | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| PE20161210A1 (es) | Anticuerpos anti-mcam y metodos de uso asociados | |
| CO2019007686A2 (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| MX2017004196A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| CL2016002892A1 (es) | Anticuerpos ang2 | |
| MX2021001604A (es) | Tratamiento del cáncer con un anticuerpo. | |
| MX2018005097A (es) | Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5. |